<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAK</journal-id>
<journal-id journal-id-type="hwp">sptak</journal-id>
<journal-id journal-id-type="nlm-ta">Ther Adv Cardiovasc Dis</journal-id>
<journal-title>Therapeutic Advances in Cardiovascular Disease</journal-title>
<issn pub-type="ppub">1753-9447</issn>
<issn pub-type="epub">1753-9455</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1753944713479995</article-id>
<article-id pub-id-type="publisher-id">10.1177_1753944713479995</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Direct renin inhibition: extricating facts from façades</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Juncos</surname><given-names>Luis</given-names></name>
</contrib>
<aff id="aff1-1753944713479995">Fundación Robert Cade, Pedro de Oñate 253, Cordoba 5003, Argentina</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1753944713479995"><email>luis.juncos@jrobertcade.org.ar</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>7</volume>
<issue>3</issue>
<fpage>153</fpage>
<lpage>167</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The renin–angiotensin system (RAS) affects vascular tone, cardiac output and kidney function. By these means the RAS plays a key role in the pathogenesis of arterial hypertension. As a result, RAS inhibition is highly effective not only in lowering blood pressure but also in reducing kidney disease progression (particularly when associated with proteinuria) and cardiovascular events.</p>
<p>Among RAS blocking agents, direct renin inhibitors have shown not only excellent efficacy in hypertension control but also pharmacologic tolerance that is comparable with other renin–angiotensin suppressors. Indeed, aliskiren, the only direct renin inhibitor available is effective in controlling blood pressure as monotherapy or in combination with other antihypertensive drugs, irrespective of patient’s age, ethnicity or sex. It is also effective in patients with metabolic syndrome, obesity and diabetes. Long-term studies comparing ‘hard endpoints’ of aliskiren therapy <italic>versus</italic> treatment with other RAS inhibitors, including cardiac and kidney protection, are currently ongoing. Combined with other antihypertensive agents, aliskiren not only improves their hypotensive response but may also lessen the adverse effects of other drugs. In high-risk patients, however, precautions should be taken when combining two or more renin–angiotensin inhibiting agents, as tissue perfusion may be highly renin-dependent in these patients and serious adverse side effects could take place.</p>
</abstract>
<kwd-group>
<kwd>aliskiren</kwd>
<kwd>hypertension</kwd>
<kwd>renin inhibition</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1753944713479995">
<title>Background</title>
<p>Lowering high blood pressure has long been a major goal in clinical practice, even before therapy-driven improvement in survival rates and outcomes were demonstrated. For years, however, therapy was intuitive and efficacy was low. The treatment goals were poorly defined, and while the better-tolerated agents had limited efficacy, the more effective drugs were poorly tolerated. These difficulties were largely resolved by a rational approach based on reducing one or both of the components of the blood pressure equation:</p>
<p><disp-formula id="disp-formula1-1753944713479995">
<mml:math display="block" id="math1-1753944713479995">
<mml:mrow>
<mml:mi>Blood</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>pressure</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>Cardiac</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>output</mml:mi>
<mml:mo>×</mml:mo>
<mml:mi>Total</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>vascular</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>peripheral</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>resistance</mml:mi>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1753944713479995" xlink:href="10.1177_1753944713479995-eq1.tif"/>
</disp-formula></p>
<p>The method entailed the use of diuretics for volume reduction, or vasodilators to control high peripheral vascular resistance. In this manner, while high blood pressure could be lowered in some patients, a significant proportion could not achieve acceptable levels. In these cases, physicians could choose either a dose uptitration of the drug already in use (with a potential rise in adverse effects), or adding a second drug with alternate hypotensive actions that did not enhance adverse effects [<xref ref-type="bibr" rid="bibr28-1753944713479995">Gifford, 1974</xref>]</p>
</sec>
<sec id="section2-1753944713479995">
<title>Plasma renin activity levels and drug choice</title>
<p>Plasma renin activity (PRA) measures angiotensin generation in a predefined time and in the presence of an angiotensinogen excess. Under these conditions, the synthesis of angiotensin depends on the amount of renin available in the sample. Hence, as a rule, PRA is a good reflection of angiotensin II (Ang II) concentration. However, not being a direct measure of circulating Ang II, care should be taken when interpreting PRA levels. Anyhow, PRA has been used in clinical practice to estimate the volume of the extracellular compartment, as it correlates inversely with PRA.</p>
<p>Indeed, 40 years ago, Laragh and colleagues grouped hypertensive patients by their volume status using PRA levels [<xref ref-type="bibr" rid="bibr11-1753944713479995">Brunner <italic>et al</italic>. 1972</xref>; <xref ref-type="bibr" rid="bibr49-1753944713479995">Laragh, 1973</xref>]. The rationale behind this proposal was that patients with low PRA have volume excess and thus should respond better to diuretics. In contrast, high renin activity in hypertensive patients denoted vasoconstriction and therefore should respond better to RAS inhibitors [<xref ref-type="bibr" rid="bibr53-1753944713479995">Man in′t Veld and den Meiracker, 1990</xref>]. This idea had limited acceptance among internists and cardiologists, mainly because no good correlation could be found in clinical practice between PRA and the hypotensive response to different kinds of drugs.</p>
<p>This lack of correspondence between PRA and drug response was confirmed after the introduction of angiotensin-converting enzyme inhibitors (ACEIs). Indeed, these drugs prevent the synthesis of Ang II and yet their therapeutic efficacy is PRA-independent. Thus, the antihypertensive actions of ACEIs, and angiotensin II–AT1 receptor blockers (ARBs) could be accounted for by Ang II dual action: vasoconstriction and renal sodium retention (due to direct tubular effects and to increased aldosterone synthesis). In other words, RAS inhibitors may affect not only the vascular tone but also fluid volume.</p>
<p>A second explanation for the lack of correlation between PRA and drug response is that circulating renin levels may not reflect tissue renin levels. Indeed, many organs (heart, blood vessels, adrenal glands, central nervous system, kidney and others) may not only synthesize RAS components, but also may store and build up such components to achieve levels that are much higher than plasma levels [<xref ref-type="bibr" rid="bibr41-1753944713479995">Kifor and Dzau, 1987</xref>; <xref ref-type="bibr" rid="bibr73-1753944713479995">Pendergrass <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr63-1753944713479995">Navar and Nishiyama, 2001</xref>, <xref ref-type="bibr" rid="bibr64-1753944713479995">2004</xref>].</p>
<p>Unfortunately, despite numerous studies, it remains challenging to discriminate between the putative roles of circulating <italic>versus</italic> local RAS effects. The evidence available indicates that both effects are important functions by themselves or combined. For instance, while Ang I and Ang II are produced in endothelia and in vascular smooth muscle, renin synthesis in these tissues has never been demonstrated, suggesting that renin must be taken up from the circulation [<xref ref-type="bibr" rid="bibr52-1753944713479995">Linz <italic>et al</italic>. 1995</xref>; <xref ref-type="bibr" rid="bibr12-1753944713479995">Campbell, 1985</xref>; <xref ref-type="bibr" rid="bibr33-1753944713479995">Hilgers <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr93-1753944713479995">van del Wal <italic>et al</italic>. 2007</xref>]. Likewise, even though most of the RAS components are also synthesized in the heart, there is no evidence that renin can be synthesized by this organ [<xref ref-type="bibr" rid="bibr17-1753944713479995">Danser <italic>et al</italic>. 1994</xref>, <xref ref-type="bibr" rid="bibr18-1753944713479995">1997</xref>; <xref ref-type="bibr" rid="bibr22-1753944713479995">Dostal et al. 2000</xref>]. This suggests that circulating renin is needed for the synthesis of angiotensin in the myocardium. Moreover, a role for circulating renin is also suggested by increased aldosterone synthesis in response to intravenous angiotensin II infusions [<xref ref-type="bibr" rid="bibr27-1753944713479995">Ganong <italic>et al</italic>. 1962</xref>; <xref ref-type="bibr" rid="bibr55-1753944713479995">Mason <italic>et al</italic>. 1976</xref>; <xref ref-type="bibr" rid="bibr9-1753944713479995">Blair-West <italic>et al</italic>. 1962</xref>]. In summary, a role for circulating renin seems indisputable and, thus, its inhibition may participate in putative beneficial effects.</p>
<p>Alternatively, local renin production takes place in the kidney, ovary, brain, uterus and others organs [<xref ref-type="bibr" rid="bibr76-1753944713479995">Re, 2001</xref>, <xref ref-type="bibr" rid="bibr77-1753944713479995">2003a</xref>, <xref ref-type="bibr" rid="bibr78-1753944713479995">2003b</xref>; <xref ref-type="bibr" rid="bibr72-1753944713479995">Paul <italic>et al</italic>. 2006</xref>]. A putative role for this local RAS is sustained by a number of theoretical estimates and experimental evidence. For instance, the equilibrium dissociation constant (K<sub>D</sub>) of the Ang II reaction with AT1 receptors suggests that circulating RAS may be insufficient to stimulate AT1 receptors. Indeed, if K<sub>D</sub> (Ang II level needed to saturate 50% of the receptors) is of the order of 10<sup>−9</sup> mol/l, the normal circulating Ang II concentrations are much lower and insufficient to saturate half of the receptors. Yet, Ang II infusions that increase the plasma levels from 10 × 10<sup>−15</sup> to only 30 × 10<sup>−15</sup> mol/ml are sufficient to increase mean blood pressure [<xref ref-type="bibr" rid="bibr15-1753944713479995">Chinn and Dusterdieck, 1972</xref>]. To explain this notion, Schalenkamp and Danser have proposed a mechanism of amplification and facilitated diffusion [<xref ref-type="bibr" rid="bibr81-1753944713479995">Schalenkamp and Danser, 2011</xref>]; through a mathematical model that considers the fluid barriers that Ang II has to cross to reach the AT1R at the vascular smooth muscle cell, the authors concluded that circulating Ang II concentration needs to be 20–30 times higher than normal plasma levels to maintain the vascular tone in resistance vessels. This means that abluminal rather than intraluminal Ang II is vital for maintaining vasoconstrictor tone. Moreover, the association rate amplification proposed, should minimize overflow of tissue Ang II into the circulation thus explaining why Ang II acts at levels far below K<sub>D</sub>, and why AT1R blockers are effective in hypertension even when PRA is low.</p>
<p>In addition, the internalization and binding of renin and prorenin to cellular receptors has been associated with increased cellular synthesis of angiotensin, subsequent generation of second messengers and induction of physiological effects. These observations not only reveal prorenin and renin to be hormones in their own right, they suggest that prorenin and renin are intracrines; that is, they are locally produced to exert local physiologic effects. Indeed, there is abundant evidence showing local synthesis of each of the components of the renin–angiotensin system (RAS) in various tissues [<xref ref-type="bibr" rid="bibr41-1753944713479995">Kifor and Dzau, 1987</xref>; <xref ref-type="bibr" rid="bibr73-1753944713479995">Pendergrass <italic>et al</italic>. 2006</xref>].</p>
<p>In the kidney for instance, RAS components reach exceedingly high concentrations in several specific compartments, suggesting regulatory actions and local production. The prototype is the proximal tubule, where all RAS components reach levels that are much higher than plasma levels (<xref ref-type="fig" rid="fig1-1753944713479995">Figure 1</xref>). This is achieved by means of an augmentation mechanism, whereupon Ang II, increases renin synthesis, instead of decreasing it [<xref ref-type="bibr" rid="bibr63-1753944713479995">Navar and Nishiyama, 2001</xref>; <xref ref-type="bibr" rid="bibr73-1753944713479995">Pendergrass <italic>et al</italic>. 2006</xref>].</p>
<fig id="fig1-1753944713479995" position="float">
<label>Figure 1.</label>
<caption>
<p>Plasma and renal angiotensin levels: low and high dietary sodium.</p>
</caption>
<graphic xlink:href="10.1177_1753944713479995-fig1.tif"/>
</fig>
<p>Because these tissue concentrations of renin and angiotensin are not mirrored in blood levels, it could explain while PRA fails to predict the blood pressure response in hypertensive patients.</p>
</sec>
<sec id="section3-1753944713479995">
<title>Pathogenic importance of RAS</title>
<p>Even though PRA does not predict the hypotensive response to RAS inhibition, its pathogenic relevance is undeniable. The worse outcomes of patients with high PRA have been long demonstrated. Moreover, such increased activity is currently considered a risk factor for myocardial infarction in hypertensive patients [<xref ref-type="bibr" rid="bibr1-1753944713479995">Alderman <italic>et al</italic>. 1991</xref>; <xref ref-type="bibr" rid="bibr2-1753944713479995">1997</xref>; <xref ref-type="bibr" rid="bibr61-1753944713479995">Muhlestein <italic>et al</italic>. 2010</xref>] suggesting that PRA inhibition could be a therapeutic goal by itself.</p>
<p>Certainly, renin-associated risks arise through Ang II effects. Therefore, preventing the conversion of Ang I to Ang II, or blocking the AT1 receptor should avoid the risk. However, ACEIs block the synthesis of Ang II only partially and conversion of Ang I to Ang II can be achieved by mean of other enzymes [<xref ref-type="bibr" rid="bibr34-1753944713479995">Hollenberg <italic>et al</italic>. 1998</xref>]. Moreover, parallel activation pathways generate angiotensin peptides capable of stimulating the AT1 receptors. These phenomena have been proposed as an explanation for the alleged ACE ‘escape’ [<xref ref-type="bibr" rid="bibr34-1753944713479995">Hollenberg <italic>et al</italic>. 1998</xref>]. Likewise, ARBs efficacy can be hampered in the presence of very high Ang II levels resulting from negative feedback (first-order kinetics). Since renin and prorenin are the exclusive entrance to the RAS, their inhibition should prevent any potential escape (<xref ref-type="fig" rid="fig2-1753944713479995">Figure 2</xref>). Actually, Gradman and colleagues found that ACEIs increase PRA by 116.3%, ARBs by 110.6% and hydrochlorothiazide by 35.4%. In contrast, aliskiren decreases PRA by 70.3%. In fact, aliskiren markedly inhibits both renin and activated prorenin [<xref ref-type="bibr" rid="bibr30-1753944713479995">Gradman <italic>et al</italic>. 2006</xref>]. In brief, Ang II escape has been reported with both ACEIs and ARBs but never with renin inhibitors [<xref ref-type="bibr" rid="bibr98-1753944713479995">Wolf and Ritz, 2005</xref>].</p>
<fig id="fig2-1753944713479995" position="float">
<label>Figure 2.</label>
<caption>
<p>Generation and feedback pathways of the renin–angiotensin system. APA, aminopeptidase A; APN, aminopeptidase N.</p>
</caption>
<graphic xlink:href="10.1177_1753944713479995-fig2.tif"/>
</fig>
<p>Another possible indication for direct RAS inhibition is that both renin and activated prorenin seem to have direct intracellular effects (before being released) that may induce hypertrophy, proliferation and fibrosis [<xref ref-type="bibr" rid="bibr66-1753944713479995">Nguyen and Danser, 2008</xref>]. For these reasons, and because diuretics, ACEIs and ARBs increase PRA, adding aliskiren may be a proper way to neutralize the intracellular effects [<xref ref-type="bibr" rid="bibr68-1753944713479995">O’Brien <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section4-1753944713479995">
<title>Renin-dependence <italic>versus</italic> volume-dependence</title>
<p>Interpreting high blood pressure as either renin-dependent or volume-dependent led to unjustified doubts on the role of RAS in high blood pressure and cardiovascular disease. In fact, based on PRA levels, renin would play a pathogenic role only in about 17% of the hypertensive patients [<xref ref-type="bibr" rid="bibr11-1753944713479995">Brunner <italic>et al</italic>. 1972</xref>; <xref ref-type="bibr" rid="bibr49-1753944713479995">Laragh, 1973</xref>]. This notion did not match clinical experience and was rebutted when Gorbea-Oppliger and colleagues showed that subpressor doses of Ang II caused persistent hypertension that was reversed by AT1 receptor antagonists, even though angiotensin levels remained unchanged [<xref ref-type="bibr" rid="bibr29-1753944713479995">Gorbea-Oppliger et al. 1994</xref>] (<xref ref-type="fig" rid="fig3-1753944713479995">Figure 3</xref>). Currently, there is no doubt that the RAS plays a key role in the development of hypertension.</p>
<fig id="fig3-1753944713479995" position="float">
<label>Figure 3.</label>
<caption>
<p>Changes in mean blood pressure following angiotensin II boluses (rapid responses to pressor doses in bolus and slow responses to ‘subpressor’ doses administered by continuous infusion).</p>
</caption>
<graphic xlink:href="10.1177_1753944713479995-fig3.tif"/>
</fig>
<p>Precisely, and based on this crucial pathogenic role of the RAS, drugs that inhibit its cascade show great effectiveness as isolated or combined therapies [<xref ref-type="bibr" rid="bibr97-1753944713479995">Wing <italic>et al</italic>. 1997</xref>; <xref ref-type="bibr" rid="bibr42-1753944713479995">Kjeldsen <italic>et al</italic>. 2002</xref>]. Other advantages that should be added to these benefits are: tolerability, antioxidant effects and the ability to offset other drugs undesired effects (edema and flashing of vasodilators, hypokalemia and insulin resistance of diuretics, etc.) [<xref ref-type="bibr" rid="bibr23-1753944713479995">Drummond <italic>et al</italic>. 2007</xref>]. Their well-known protective effects on the heart, blood vessels, kidney, and central nervous system, among others, could be considered additional benefits [<xref ref-type="bibr" rid="bibr21-1753944713479995">Dell’Italia, 2011</xref>; <xref ref-type="bibr" rid="bibr83-1753944713479995">Schrader <italic>et al</italic>. 2005</xref>].</p>
</sec>
<sec id="section5-1753944713479995">
<title>ACEIs, ARBs and direct renin inhibitors: differential features</title>
<p>Having reviewed the favorable features of RAS inhibition, it is important to define potential differences in terms of effectiveness and tolerability exhibited by the different classes of RAS inhibitors: ACEIs, ARBs and DRIs. The few comparative studies with different types of RAS inhibitors are not conclusive due to large variations in study populations [<xref ref-type="bibr" rid="bibr74-1753944713479995">Pfeffer <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr54-1753944713479995">Mann <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr75-1753944713479995">Pitt, 2000</xref>]. However, the excellent efficacy and tolerability profiles of ACEIs and ARBs are shared with aliskiren [<xref ref-type="bibr" rid="bibr31-1753944713479995">Gradman <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr5-1753944713479995">Andersen <italic>et al</italic>. 2007</xref>]. Moreover, aliskiren does not affect substance P synthesis or kinin metabolism and, therefore, it is not expected to cause dry cough or angioneurotic edema.</p>
<p>Aliskiren has shown therapeutic advantages in some trials [<xref ref-type="bibr" rid="bibr5-1753944713479995">Andersen <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr88-1753944713479995">Solomon <italic>et al</italic>. 2009</xref>] (<xref ref-type="table" rid="table1-1753944713479995">Table 1</xref>). However, should ‘superiority’ exist for one kind of inhibitor over the other, the emergent question would be: how could an ACEI, an ARB or a direct renin inhibitor (DRI) produce different results if pharmacologically equivalent doses are used?</p>
<table-wrap id="table1-1753944713479995" position="float">
<label>Table 1.</label>
<caption>
<p>Studies comparing aliskiren with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor antagonist. Values indicate systolic blood pressure (SBP) and diastolic blood pressure (DBP) reductions <italic>versus</italic> baseline values. (Doses are indicated as maximum allowed by protocol). Two studies showed no inferiority, whereas the remainder showed better blood pressure lowering by aliskiren.</p>
</caption>
<graphic alternate-form-of="table1-1753944713479995" xlink:href="10.1177_1753944713479995-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left"><bold>Study</bold></th>
<th align="left">Δ SBP difference (mmHg)</th>
<th align="left">Δ DBP difference (mm/Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3"><bold>Western Pennsylvania Hospital</bold> [<xref ref-type="bibr" rid="bibr31-1753944713479995">Gradman <italic>et al</italic>. 2005</xref>]</td>
</tr>
<tr>
<td>Aliskiren (600 mg/day)</td>
<td>–15.7</td>
<td>–11.5</td>
</tr>
<tr>
<td>Ibersartan (150 mg/day)</td>
<td>–12.5*</td>
<td>–8.9*</td>
</tr>
<tr>
<td colspan="3"><bold>Multicenter aliskiren <italic>versus</italic> irbesartan</bold> [Krone <italic>et al</italic>. 2010]</td>
</tr>
<tr>
<td>Aliskiren (300 mg/day)</td>
<td>–13.8</td>
<td>–7.1</td>
</tr>
<tr>
<td>Irbesartan</td>
<td>–5.8*</td>
<td>–2.8*</td>
</tr>
<tr>
<td colspan="3"><bold>Ageless</bold> [<xref ref-type="bibr" rid="bibr24-1753944713479995">Duprez <italic>et al</italic>. 2010</xref>]</td>
</tr>
<tr>
<td>Aliskiren (300 mg/day), HCTZ</td>
<td>–29.6</td>
<td>–12.0</td>
</tr>
<tr>
<td>Ramipril (10 mg/day), HCTZ</td>
<td>–26.4*</td>
<td>–10.4*</td>
</tr>
<tr>
<td colspan="3"><bold>University of Alabama</bold> [<xref ref-type="bibr" rid="bibr69-1753944713479995">Oparil <italic>et al</italic>. 2007</xref>]</td>
</tr>
<tr>
<td>Aliskiren</td>
<td>–13.0</td>
<td>–12.7</td>
</tr>
<tr>
<td>Valsartan</td>
<td>–9.0</td>
<td>–9.7</td>
</tr>
<tr>
<td colspan="3"><bold>Chelsea, MI</bold> [<xref ref-type="bibr" rid="bibr100-1753944713479995">Yarows, 2008</xref>]</td>
</tr>
<tr>
<td>Aliskiren (300 mg/day)</td>
<td>–15</td>
<td>–12</td>
</tr>
<tr>
<td>Valsartan (320 mg/day)</td>
<td>–17</td>
<td>–11</td>
</tr>
<tr>
<td colspan="3"><bold>Reykjavik, Iceland</bold> [<xref ref-type="bibr" rid="bibr3-1753944713479995">Andersen <italic>et al</italic>. 2008</xref>]</td>
</tr>
<tr>
<td>Aliskiren (300 mg/day)</td>
<td>–17.9</td>
<td>–13.2</td>
</tr>
<tr>
<td>Ramipril (10 mg/day)</td>
<td>–15.2*</td>
<td>–12.0*</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The evaluation of potential differences in efficacy requires the consideration of changes induced by each drug in all levels of the RAS cascade. For instance, angiotensin-converting enzyme (ACE) inhibition decreases Ang II synthesis and by negative feedback it increases the syntheses of pre-prorenin, prorenin, renin and angiotensin I [<xref ref-type="bibr" rid="bibr11-1753944713479995">Brunner <italic>et al</italic>. 1972</xref>; <xref ref-type="bibr" rid="bibr49-1753944713479995">Laragh, 1973</xref>]. If ACE were the only enzyme capable of converting Ang I into Ang II, the process would end at this point. However, many tissues have enzymes other than ACE that are capable of converting angiotensin I into Ang II (<xref ref-type="fig" rid="fig4-1753944713479995">Figure 4</xref>). For instance, the heart expresses tonins, cathepsins, chymases and trypsin that can synthesize Ang II from Ang I [<xref ref-type="bibr" rid="bibr34-1753944713479995">Hollenberg <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr65-1753944713479995">Neves <italic>et al</italic>. 1996</xref>; <xref ref-type="bibr" rid="bibr44-1753944713479995">Kramkowski <italic>et al</italic>. 2006</xref>]. As a result; attempts to inhibit the RAS could fail to induce the desired effects on vasoconstriction and on renal sodium excretion. In brief, converting enzyme plays no exclusive role on Ang I. Alternative enzymatic pathways could generate Ang II from Ang I [<xref ref-type="bibr" rid="bibr99-1753944713479995">Wolny <italic>et al</italic>. 1997</xref>].</p>
<fig id="fig4-1753944713479995" position="float">
<label>Figure 4.</label>
<caption>
<p>Carboxipeptidases and aminopeptidases involved in the activation of the renin angiotensin system. The multiple pathways provide routes of “escape” for the synthesis of various angiotensin peptides.</p>
</caption>
<graphic xlink:href="10.1177_1753944713479995-fig4.tif"/>
</fig>
<p>Similarly AT1 receptor blockade leads to a feedback response that increases the synthesis of all components of the RAS cascade, including Ang II. For this, AT1 receptor blockers are compelled to compete for the receptor with the higher Ang II levels (first-order kinetics), thus decreasing their specific blocking effects. In addition, other recently described receptors could be activated by Ang II-or Ang I-derived peptides excess (<xref ref-type="fig" rid="fig4-1753944713479995">Figure 4</xref>) [<xref ref-type="bibr" rid="bibr60-1753944713479995">Mogi <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr19-1753944713479995">de Gasparo <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr43-1753944713479995">Kostenis, 2005</xref>].</p>
<p>In contrast, although DRIs also increase renin synthesis, PRA ‘activity’ is powerfully blocked and, thus, the entire RAS cascade is inhibited [<xref ref-type="bibr" rid="bibr67-1753944713479995">Nussberger <italic>et al</italic>. 2002</xref>]. Moreover, aliskiren (the available information on enalkiren, remikiren or zankiren is insufficient) has the ability to enter the cell where it could inhibit not only renin (before its release), but also activated prorenin [<xref ref-type="bibr" rid="bibr46-1753944713479995">Krop <italic>et al</italic>. 2008</xref>]. The latter exerts cellular and systemic effects that are similar to those of renin. Thus, aliskiren could have beneficial intracellular effects [<xref ref-type="bibr" rid="bibr77-1753944713479995">Re, 2003</xref>; <xref ref-type="bibr" rid="bibr80-1753944713479995">Saris <italic>et al</italic>. 2006</xref>], preventing renin from inducing apoptosis, fibrosis and cell degeneration [<xref ref-type="bibr" rid="bibr87-1753944713479995">Singh et al. 2008</xref>; <xref ref-type="bibr" rid="bibr7-1753944713479995">Baker and Kumar, 2006</xref>]. Truly, intracellular renin activation is unexpected, since renin (like a myriad of proteins produced by cells) is retained within cytoplasmic vacuoles or stored in cell membrane ‘vesicles’ until its release [<xref ref-type="bibr" rid="bibr14-1753944713479995">Castrop <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr84-1753944713479995">Sealey and Laragh, 2007</xref>; <xref ref-type="bibr" rid="bibr59-1753944713479995">Mendez et al. 2011</xref>].</p>
<p>Nevertheless, the finding of a second transcription start site within the renin gene predicted the synthesis of a shorter form of prorenin. This ‘truncated’ form of prorenin lacks the ‘signal peptide’ that blocks its enzymatic activity [<xref ref-type="bibr" rid="bibr51-1753944713479995">Lee-Kirsch <italic>et al</italic>. 1999</xref>]. Normally, by gluing the prosegment to the rest of the molecule, the signal peptide suppresses renin enzymatic action [<xref ref-type="bibr" rid="bibr79-1753944713479995">Reudelhuber, 2009</xref>; <xref ref-type="bibr" rid="bibr47-1753944713479995">Kumar and Boim, 2009</xref>]. Consequently, ‘active’ truncated prorenin could play harmful effects within the cell [<xref ref-type="bibr" rid="bibr77-1753944713479995">Re, 2003</xref>]. Aliskiren’s special ability to enter the cells [<xref ref-type="bibr" rid="bibr46-1753944713479995">Krop <italic>et al</italic>. 2008</xref>] suggests that these deleterious intracellular effects from a truncated form of prorenin could also be inhibited. Such putative action however has not been tested so far.</p>
</sec>
<sec id="section6-1753944713479995">
<title>Paradoxical effect of direct renin inhibition</title>
<p>Direct renin inhibition largely accounts for its therapeutic effectiveness. However, it has been suggested that increased renin synthesis due to negative feedback could lead to a paradoxical rise in blood pressure [<xref ref-type="bibr" rid="bibr84-1753944713479995">Sealey and Laragh, 2007</xref>, <xref ref-type="bibr" rid="bibr85-1753944713479995">2009</xref>]. This rationale does not take into account the fact that regardless of how high renin concentration is, renin activity is inhibited with effectiveness close to 100% [<xref ref-type="bibr" rid="bibr91-1753944713479995">Stanton <italic>et al</italic>. 2003</xref>]. Resistant cases showing trivial blood pressure rises are expected in any large hypertension trial, a phenomenon probably related to individual variations in compliance, dietary salt intake and others. The ‘prohypertensive’ hypothesis has not been shown in trials reporting on aliskiren efficacy in various populations [<xref ref-type="bibr" rid="bibr57-1753944713479995">Menard and Azizi, 2007</xref>; <xref ref-type="bibr" rid="bibr90-1753944713479995">Stanton et al. 2010</xref>]. In contrast, aliskiren monotherapy has been shown to reduce blood pressure regardless of the PRA levels [<xref ref-type="bibr" rid="bibr82-1753944713479995">Schmieder <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr89-1753944713479995">Stanton <italic>et al</italic>. 2009</xref>].</p>
<p>In summary, both renin and prorenin play a pathogenic role in high blood pressure. It would appear then that the main advantage of direct renin inhibition rests on effects involving both renin and prorenin within the cell and in the circulation. The intracellular inhibition could reverse direct intracellular effects, including those caused by truncated prorenin. These concepts are supported by several efficacy and tolerability studies.</p>
</sec>
<sec id="section7-1753944713479995">
<title>Clinical efficacy of aliskiren</title>
<sec id="section8-1753944713479995">
<title>Effectiveness by gender and age</title>
<p>Several clinical studies have shown that direct renin inhibition by aliskiren effectively lowers systolic and diastolic blood pressure and that this reduction is dose-dependent (<xref ref-type="table" rid="table1-1753944713479995">Table 1</xref>). For instance, the AGELESS Trial (Aliskiren for Geriatric Lowering of Systolic Hypertension) showed that aliskiren (either as monotherapy or combined with hydrochloro-thiazide) is more effective than ramipril at reducing systolic and diastolic blood pressure in patients older than 65 years with systolic hypertension [<xref ref-type="bibr" rid="bibr24-1753944713479995">Duprez <italic>et al</italic>. 2010</xref>].</p>
<table-wrap id="table2-1753944713479995" position="float">
<label>Table 2.</label>
<caption>
<p>Blood pressure reduction in hypertensive patients in several populations. Values indicate systolic blood pressure (SBP) and diastolic blood pressure (DBP) reductions (in mm/Hg) <italic>versus</italic> baseline values (*<italic>p</italic> &lt; 0.05) and reductions <italic>(in mm/Hg) versus</italic> lower dose (#<italic>p</italic> &lt; 0.05).</p>
</caption>
<graphic alternate-form-of="table2-1753944713479995" xlink:href="10.1177_1753944713479995-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left"><bold>Study</bold></th>
<th align="left">Δ SBP difference (mmHg)</th>
<th align="left">Δ DBP difference (mm/Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3"><bold>Aliskiren in essential hypertension</bold> [<xref ref-type="bibr" rid="bibr31-1753944713479995">Gradman <italic>et al</italic>. 2005</xref>]</td>
</tr>
<tr>
<td>150 mg/day</td>
<td>–11.4*</td>
<td>–9.3*</td>
</tr>
<tr>
<td>300 mg/day</td>
<td>–15.8 #</td>
<td>–11.8 #</td>
</tr>
<tr>
<td>600 mg/day</td>
<td>– 15.7</td>
<td>–11.5</td>
</tr>
<tr>
<td colspan="3"><bold>Aliskiren and age</bold> [<xref ref-type="bibr" rid="bibr16-1753944713479995">Dahlöf <italic>et al</italic>. 2007</xref>]</td>
</tr>
<tr>
<td>&lt; 65 year old - 150 mg/day</td>
<td>–12.2*</td>
<td>–6.1*</td>
</tr>
<tr>
<td>&lt; 65 year old - 300 mg/day</td>
<td>–15.3 #</td>
<td>–9.2 #</td>
</tr>
<tr>
<td>&gt; 65 year old - 150 mg/day</td>
<td>–13.4*</td>
<td>–9.0*</td>
</tr>
<tr>
<td>&gt; 65 year old - 300 mg/day</td>
<td>–14.6*</td>
<td>–88.97 #</td>
</tr>
<tr>
<td colspan="3"><bold>Aliskiren and gender</bold> [<xref ref-type="bibr" rid="bibr16-1753944713479995">Dahlöf <italic>et al</italic>. 2007</xref>]</td>
</tr>
<tr>
<td>Men - 150 mg/day</td>
<td>–11.4</td>
<td>–6.5*</td>
</tr>
<tr>
<td>Men - 300 mg/day</td>
<td>–14.6</td>
<td>–9.7*</td>
</tr>
<tr>
<td>Women - 150 mg/day</td>
<td>–14.1*</td>
<td>–6.9</td>
</tr>
<tr>
<td>Women - 300 mg/day</td>
<td>–16.1#</td>
<td>–8.9*</td>
</tr>
<tr>
<td colspan="3"><bold>Diabetes mellitus</bold> [<xref ref-type="bibr" rid="bibr92-1753944713479995">Uresin <italic>et al</italic>. 2007</xref>]</td>
</tr>
<tr>
<td>300 mg/day - All</td>
<td>–14.7*</td>
<td>–11.3*</td>
</tr>
<tr>
<td colspan="3"><bold>Impaired renal function</bold> [<xref ref-type="bibr" rid="bibr96-1753944713479995">Weir <italic>et al</italic>. 2007</xref>]</td>
</tr>
<tr>
<td>Aliskiren (150 mg/day), &lt;60 ml/min</td>
<td>–10.1*</td>
<td>–10.4*</td>
</tr>
<tr>
<td>Aliskiren (300 mg/day), 60 ml/min</td>
<td>–14.7*</td>
<td>–11.4*</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section9-1753944713479995">
<title>Long-term effectiveness</title>
<p>A very interesting pharmacological aspect of aliskiren is that direct renin inhibition produces a long-term pharmacological effect, particularly for treatments lasting several weeks [<xref ref-type="bibr" rid="bibr4-1753944713479995">Andersen <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr86-1753944713479995">Sica <italic>et al</italic>. 2008</xref>] (<xref ref-type="fig" rid="fig5-1753944713479995">Figure 5</xref>). Indeed, the vascular effects of aliskiren last longer than expected based on its half-life. This is particularly true in patients on long-term therapy who remain under control for several days and in some cases for several weeks after drug discontinuation. Krop and colleagues have shown that aliskiren accumulates in renin granules in the kidney, thus allowing long-lasting RAS blockade beyond the half-life of this drug [<xref ref-type="bibr" rid="bibr46-1753944713479995">Krop <italic>et al</italic>. 2008</xref>]. These lasting effects from aliskiren could be of key importance, bearing in mind the extremely low compliance reported in the treatment of hypertension.</p>
<fig id="fig5-1753944713479995" position="float">
<label>Figure 5.</label>
<caption>
<p>Antihypertensive effect of aliskiren following the discontinuation of long-term treatment.</p>
</caption>
<graphic xlink:href="10.1177_1753944713479995-fig5.tif"/>
</fig>
</sec>
<sec id="section10-1753944713479995">
<title>Effectiveness in clinical groups</title>
<sec id="section11-1753944713479995">
<title>Essential hypertension</title>
<p>For aliskiren, the largest evidence regarding hypertension control comes from patients with primary hypertension (<xref ref-type="table" rid="table1-1753944713479995">Table 1</xref>). In these patients, aliskiren reduces blood pressure with similar or higher effectiveness compared with drugs commonly used as first-line treatment [<xref ref-type="bibr" rid="bibr25-1753944713479995">Frampton and Curran, 2007</xref>; <xref ref-type="bibr" rid="bibr95-1753944713479995">Villamil <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section12-1753944713479995">
<title>High blood pressure and congestive heart failure</title>
<p>Aliskiren has also shown great efficacy when arterial hypertension and heart failure coexist. Indeed, the ALOFT trial [<xref ref-type="bibr" rid="bibr56-1753944713479995">McMurray <italic>et al</italic>. 2008</xref>], comparing aliskiren with placebo added to standard of care therapy in heart failure, showed an excellent tolerability profile with clinical recovery and hemodynamic improvement in terms of left ventricular function (as assessed by echocardiography), along with reduction of brain natriuretic peptide (BNP) and NT-proBNP (n-terminal pro-brain natriuretic peptide) levels [<xref ref-type="bibr" rid="bibr50-1753944713479995">Latini <italic>et al</italic>. 2002</xref>] (<xref ref-type="fig" rid="fig6-1753944713479995">Figure 6</xref>). These parameters correlate with the hemodynamic status. Briefly, adding aliskiren to standard of care therapy in patients with heart failure produces comparable tolerability, reduction of BNP, NT-proBNP, aldosterone and renin activity levels and improvement in left ventricular function by ultrasound. These beneficial effects of aliskiren were confirmed in the ALLAY trial. Indeed, aliskiren was as effective as losartan in terms of blood pressure control and in reversing left ventricular hypertrophy [<xref ref-type="bibr" rid="bibr88-1753944713479995">Solomon <italic>et al</italic>. 2009</xref>] (<xref ref-type="fig" rid="fig7-1753944713479995">Figure 7</xref>).</p>
<fig id="fig6-1753944713479995" position="float">
<label>Figure 6.</label>
<caption>
<p>Brain natriuretic peptide (BNP) levels in several clinical studies. Aliskiren <italic>versus</italic> other antihypertensive agents.</p>
</caption>
<graphic xlink:href="10.1177_1753944713479995-fig6.tif"/>
</fig>
<fig id="fig7-1753944713479995" position="float">
<label>Figure 7.</label>
<caption>
<p>Aliskiren/losartan combination reduces left ventricular mass index ~20% more than losartan monotherapy (ALLAY [Solomon <italic>et al</italic>. 2008]).</p>
</caption>
<graphic xlink:href="10.1177_1753944713479995-fig7.tif"/>
</fig>
</sec>
<sec id="section13-1753944713479995">
<title>High blood pressure and diabetes</title>
<p>Preliminary studies with aliskiren strongly suggest a dose-dependent efficacy in the treatment of hypertension in diabetic patients [<xref ref-type="bibr" rid="bibr20-1753944713479995">Deinum <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr40-1753944713479995">Kawazu <italic>et al</italic>. 2004</xref>]. The AVOID study showed a remarkable reduction in proteinuria in patients treated with aliskiren, beyond that achieved with losartan at maximal doses [<xref ref-type="bibr" rid="bibr70-1753944713479995">Parving <italic>et al</italic>. 2008</xref>].</p>
</sec>
<sec id="section14-1753944713479995">
<title>High blood pressure and metabolic syndrome</title>
<p>Krone and colleagues compared the effects of aliskiren 300 mg/day with irbesartan 300 mg/day in hypertensive patients with metabolic syndrome [<xref ref-type="bibr" rid="bibr45-1753944713479995">Krone <italic>et al</italic>. 2011</xref>]. A larger proportion of aliskiren patients showed blood pressure reduction to 135/85 mmHg compared with irbesartan (29.2% aliskiren <italic>versus</italic> 16.7% irbesartan). Both drugs exhibited similar effects in terms of blood glucose, lipid profile, inflammation biomarkers levels and cardiovascular risk. Likewise, aliskiren efficacy has also been shown in obese populations [<xref ref-type="bibr" rid="bibr38-1753944713479995">Jordan <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section15-1753944713479995">
<title>High blood pressure and chronic kidney disease</title>
<p>Aliskiren should be an excellent choice in patients with chronic kidney disease (CKD) [<xref ref-type="bibr" rid="bibr13-1753944713479995">Campbell <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr3-1753944713479995">Andersen et al. 2008</xref>]. Expectations are particularly high in patients with diabetic nephropathy in whom their frequent high prorenin levels may play an important pathogenic role [<xref ref-type="bibr" rid="bibr37-1753944713479995">Jennings <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr58-1753944713479995">Mogensen <italic>et al</italic>. 2000</xref>]. Aliskiren inhibits both renin and prorenin activity [<xref ref-type="bibr" rid="bibr67-1753944713479995">Nussberger <italic>et al</italic>. 2002</xref>]. Unfortunately, the ALTITUDE study [<xref ref-type="bibr" rid="bibr71-1753944713479995">Parving <italic>et al</italic>. 2012</xref>] approached renal protection from a double blocking standpoint in patients at high cardiovascular risk and had to be discontinued due to adverse effects considered to be the result of the vigorous RAS suppression. Regrettably, a long-term trial comparing renal function effects of direct renin inhibition with ACEIs or ARBs is not available. Be that as it may, the dual RAS blockade has fallen in disregard but the question remains open, in particular in patients with CKD and evidence of progressive renal injury.</p>
</sec>
</sec>
</sec>
<sec id="section16-1753944713479995">
<title>Dual RAS blockade</title>
<p>The few studies intended to assess dual RAS blockade have been largely contradictory [<xref ref-type="bibr" rid="bibr58-1753944713479995">Mogensen <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr62-1753944713479995">Nakao et al. 2004</xref>; <xref ref-type="bibr" rid="bibr48-1753944713479995">Kunz et al. 2008</xref>; <xref ref-type="bibr" rid="bibr101-1753944713479995">Yusuf <italic>et al</italic>. 2008</xref>]. While seemingly beneficial in the ALLAY study, where the combination with losartan showed clear advantages over monotherapy [<xref ref-type="bibr" rid="bibr88-1753944713479995">Solomon <italic>et al</italic>. 2009</xref>], the results where negative in the ONTARGET trial [<xref ref-type="bibr" rid="bibr54-1753944713479995">Mann <italic>et al</italic>. 2008</xref>] and disappointing in the ALTITUDE study [<xref ref-type="bibr" rid="bibr71-1753944713479995">Parving <italic>et al</italic>. 2012</xref>]. A possible explanation for these contradictions could be that dual blockade has been used nonspecifically; omitting situations where double or even triple RAS blockade could be most useful. One example is the ONTARGET trial, where it was concluded that telmisartan combined with ramipril had no added benefit and could be even detrimental [<xref ref-type="bibr" rid="bibr54-1753944713479995">Mann <italic>et al</italic>. 2008</xref>]. However, it is difficult to support the use of the dual blockade approach in patients with normal or near-normal baseline blood pressure. Indeed, 142/82 mmHg was the mean baseline value in ONTARGET patients and 137/74 mmHg in the ALTITUDE study. Patients treated with dual RAS inhibition and whose basal blood pressure values were below this average could have suffered episodes of critically low coronary, brain or kidney perfusion.</p>
<p>The ONTARGET investigators concluded that drug combination did not exhibit any benefit in terms of kidney function. This conclusion seems unjustified for several reasons: (a) only a few patients had proteinuria (damage prevention could hardly be demonstrated where no active damage seemed evident, in a short-term study and with near-normal blood pressure levels; (b) kidney function was normal on average (mean value: 73.6 ml/min); (c) only 36.7% of the population were diabetics and 68.5% were hypertensive.</p>
<p>In addition to these serious issues, other questions arise. For instance, the ONTARGET study was not powered to detect changes in different renal outcomes (∼600 of &gt;3000 were specifically renal outcomes). Mortality rate and acute hemodialysis (HD), not always related to kidney disease progression, were endpoints added to give statistical power to renal outcomes. In this regard, if acute HD is excluded, no difference persists in these kidney-related outcomes. Nonetheless, the rates of HD and increased serum creatinine were similar between groups (glomerular filtration rate [GFR] drop is expected and even desired, since it indicates glomerular pressure reduction). Indeed, in several studies, RAS inhibitors have shown to decrease glomerular filtration rate via a hemodynamic mechanism that is not overtly detrimental, provided that serum electrolyte levels are not markedly changed. In fact, once treatment is initiated, patients with higher serum creatinine levels obtain the highest cardiovascular benefits [<xref ref-type="bibr" rid="bibr6-1753944713479995">Apperloo <italic>et al</italic>. 1997</xref>; <xref ref-type="bibr" rid="bibr8-1753944713479995">Bakris and Weir, 2000</xref>]. This notion has been recently confirmed in a <italic>post hoc</italic> analysis of the RENAAL study. Indeed, patients with larger falls in GFR showed better long-term preservation of kidney function [<xref ref-type="bibr" rid="bibr35-1753944713479995">Holtkamp <italic>et al</italic>. 2011</xref>].</p>
<p>Other known limitations in the ONTARGET trial include: (a) albuminuria was not assessed on a yearly basis; (b) serum creatinine was measured with nonstandardized or centralized methods; (c) doubling of serum creatinine was not confirmed; and (d) indication of HD was arbitrary and nonprotocol-specified. In 98 patients the reason for chronic HD was undefined.</p>
<p>Be that as it may, in both ONTARGET and ALTITUDE most of the serious adverse effects could have been the result of poor perfusion pressure, a predictable complication in high-risk patients. For instance, in ALTITUDE, hypotensive episodes occurred more frequently when aliskiren was added to a therapy based on an ACEI or an AR1T receptor antagonist, in patients who were older than 65 years old, with lower pulse pressure or taking loop diuretics.</p>
<p>Certainly, falls, fainting, hyperkalemia and incre-ased serum creatinine are well-known complications of poor organ perfusion and therefore avoidable. In the ALTITUDE trial, patients with serum potassium concentrations greater than 5 mMol/l were randomized to dual drug treatment. This is important, bearing in mind that trial definitions may not reflect the clinical significance of a side effect. For instance, combination therapy is associated with an increased risk of moderate hyperkalemia (serum potassium &gt;5.5 mEq/l) but not of clinically significant hyperkalemia (serum potassium &gt;6 mEq/l) compared with monotherapy [<xref ref-type="bibr" rid="bibr32-1753944713479995">Harel <italic>et al</italic>. 2012</xref>]. Be that as it may, these studies clearly show that combined RAS inhibitors should be avoided in patients with basal normal or nearly normal blood pressure and in those with basal serum potassium concentration greater than 5 mEq/l.</p>
<p>The fact remains that aliskiren in combination with an ARB or an ACEI offers potential cardiorenal benefits, and its utilization has demonstrated a good tolerability profile compared with placebo, particularly in patients at high risk for congestive heart failure, diabetes mellitus or CKD [<xref ref-type="bibr" rid="bibr88-1753944713479995">Solomon <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr56-1753944713479995">McMurray <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr20-1753944713479995">Deinum <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr40-1753944713479995">Kawazu <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr26-1753944713479995">Freiberger <italic>et al</italic>. 2009</xref>]. In CKD, it should be kept in mind that the goal is not only blood pressure control, but also proteinuria reduction. High protein excretion rate is a risk factor for kidney disease progression, and its reversion delays progression of CKD [<xref ref-type="bibr" rid="bibr10-1753944713479995">Brenner <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr36-1753944713479995">Jafar <italic>et al</italic>. 2001</xref>].</p>
</sec>
<sec id="section17-1753944713479995">
<title>Tolerability and safety</title>
<p>Aliskiren has shown an excellent tolerability profile that is comparable with or higher than that of other RAS inhibitors [<xref ref-type="bibr" rid="bibr31-1753944713479995">Gradman <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr94-1753944713479995">Verdecchia <italic>et al</italic>. 2010</xref>]. For example, in the AGELESS study, aliskiren therapy was associated with a lesser incidence of adverse effects compared with ramipril (70% less undesired effects with aliskiren, compared with ramipril) [<xref ref-type="bibr" rid="bibr24-1753944713479995">Duprez <italic>et al</italic>. 2010</xref>]</p>
<p>In summary, in light of new knowledge on RAS components, the approach to high blood pressure treatment continues developing encouragingly. Among all available agents, those inhibiting the RAS show clear pathogenic and pharmacokinetic advantages, as well as an excellent tolerability profile. Particularly, direct renin inhibition appears to be not only the most recent but also a promising advance in the search of an effective control for high blood pressure, in particular, when accompanied by CKD.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>Dr Juncos has no relation or business interests with any pharmaceutical company, and does not receive or has received any (direct or indirect) research fund from any company that produces medications or medical devices. The author is not a consultant in any pharmaceutical company, and holds no shares or investment of any nature in any pharmaceutical company.</p>
<p>Dr Juncos participated as an investigator in the ALTITUDE study (a randomized, double-blind, placebo-controlled, parallel group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alderman</surname><given-names>M.</given-names></name>
<name><surname>Madhavan</surname><given-names>S.</given-names></name>
<name><surname>Ooi</surname><given-names>W.</given-names></name>
<name><surname>Cohen</surname><given-names>H.</given-names></name>
<name><surname>Sealey</surname><given-names>J.</given-names></name>
<name><surname>Laragh</surname><given-names>J.</given-names></name>
</person-group> (<year>1991</year>) <article-title>Association of the renin angiotensin profile with the risk of myocardial infarction in patients with hypertension</article-title>. <source>N Engl J Med</source> <volume>324</volume>: <fpage>1098</fpage>–<lpage>2104</lpage>.</citation>
</ref>
<ref id="bibr2-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alderman</surname><given-names>M.</given-names></name>
<name><surname>Ooi</surname><given-names>W.</given-names></name>
<name><surname>Cohen</surname><given-names>H.</given-names></name>
<name><surname>Madhavan</surname><given-names>S.</given-names></name>
<name><surname>Sealey</surname><given-names>J.</given-names></name>
<name><surname>Laragh</surname><given-names>J.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Plasma rennin activity: a risk factor for myocardial infarction in hypertensive patients</article-title>. <source>Am J Hypertens</source> <volume>10</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr3-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>K.</given-names></name>
<name><surname>Weinberger</surname><given-names>M.</given-names></name>
<name><surname>Constance</surname><given-names>C.</given-names></name>
<name><surname>Baek</surname><given-names>I.</given-names></name>
<name><surname>Keefe</surname><given-names>D.</given-names></name>
<name><surname>Prescott</surname><given-names>M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Aliskiren-based therapy provides long-term antiproteinuric effects in patients with hypertension and proteinuria: subgroup analysis of a 6-month, randomized, double-blind trial</article-title>. <source>J Am Soc Nephrol</source> <volume>19</volume>: <fpage>616A</fpage>.</citation>
</ref>
<ref id="bibr4-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>K.</given-names></name>
<name><surname>Weinberger</surname><given-names>M.</given-names></name>
<name><surname>Constance</surname><given-names>C.</given-names></name>
<name><surname>Ali</surname><given-names>M.</given-names></name>
<name><surname>Jin</surname><given-names>J.</given-names></name>
<name><surname>Prescott</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <volume>10</volume>: <fpage>157</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr5-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>K.</given-names></name>
<name><surname>Weinberger</surname><given-names>M.</given-names></name>
<name><surname>Egan</surname><given-names>B</given-names></name><etal/>
</person-group>(<year>2007</year>) <article-title>Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: a 6-month, randomized, double-blind trial</article-title>. <source>J Hypertens</source> <volume>25</volume>(<issue>2</issue>): <fpage>S373</fpage>.</citation>
</ref>
<ref id="bibr6-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Apperloo</surname><given-names>A.</given-names></name>
<name><surname>de Zeeuw</surname><given-names>D.</given-names></name>
<name><surname>de Jong</surname><given-names>P.</given-names></name>
</person-group> (<year>1997</year>) <article-title>A short term antihypertensive treatment induced fall in glomerular filtration rate predicts long term stability of renal function</article-title>. <source>Kidney Int</source> <volume>51</volume>: <fpage>793</fpage>–<lpage>797</lpage>.</citation>
</ref>
<ref id="bibr7-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baker</surname><given-names>K.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Intracellular angiotensin II induces cell proliferation independent of AT<sub>1</sub> receptor</article-title>. <source>Am J Physiol-Cell Physiol</source> <volume>291</volume>: <fpage>C995</fpage>–<lpage>C1001</lpage>.</citation>
</ref>
<ref id="bibr8-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakris</surname><given-names>G.</given-names></name>
<name><surname>Weir</surname><given-names>M.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause of concern?</article-title> <source>Arch Intern Med</source> <volume>160</volume>: <fpage>685</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr9-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blair-West</surname><given-names>J.</given-names></name>
<name><surname>Coghlan</surname><given-names>J.</given-names></name>
<name><surname>Denton</surname><given-names>D.</given-names></name>
<name><surname>Goding</surname><given-names>J.</given-names></name>
<name><surname>Munro</surname><given-names>J.</given-names></name>
<name><surname>Peterson</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>1962</year>) <article-title>Hormonal stimulation of adrenocortical secretion</article-title>. <source>J Clin Invest</source> <volume>41</volume>: <fpage>1606</fpage>–<lpage>1627</lpage>.</citation>
</ref>
<ref id="bibr10-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brenner</surname><given-names>B.</given-names></name>
<name><surname>Cooper</surname><given-names>M.</given-names></name>
<name><surname>de Zeeuw</surname><given-names>D.</given-names></name>
<name><surname>Keane</surname><given-names>W.</given-names></name>
<name><surname>Mitch</surname><given-names>W.</given-names></name>
<name><surname>Parving</surname><given-names>H.</given-names></name><etal/>
</person-group>. for <collab>the RENAAL Study Investigators</collab> (<year>2001</year>) <article-title>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy</article-title>. <source>N Engl J Med</source> <volume>345</volume>: <fpage>861</fpage>–<lpage>869</lpage>.</citation>
</ref>
<ref id="bibr11-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunner</surname><given-names>H.</given-names></name>
<name><surname>Laragh</surname><given-names>J.</given-names></name>
<name><surname>Baer</surname><given-names>L.</given-names></name>
<name><surname>Newton</surname><given-names>M.</given-names></name>
<name><surname>Goodwin</surname><given-names>F.</given-names></name>
<name><surname>Krakoff</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>1972</year>) <article-title>Essential hypertension: renin and aldosterone, heart attack and stroke</article-title>. <source>N Engl J Med</source> <volume>286</volume>: <fpage>441</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr12-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>D.</given-names></name>
</person-group> (<year>1985</year>) <article-title>The site of angiotensin production</article-title>. <source>J Hypertens</source> <volume>3</volume>: <fpage>199</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr13-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>R.</given-names></name>
<name><surname>Sangalli</surname><given-names>F.</given-names></name>
<name><surname>Perticucci</surname><given-names>E.</given-names></name>
<name><surname>Aros</surname><given-names>C.</given-names></name>
<name><surname>Viscarra</surname><given-names>C.</given-names></name>
<name><surname>Perna</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies</article-title>. <source>Kidney Int</source> <volume>63</volume>: <fpage>1094</fpage>–<lpage>1103</lpage>.</citation>
</ref>
<ref id="bibr14-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castrop</surname><given-names>H.</given-names></name>
<name><surname>Höcherl</surname><given-names>K.</given-names></name>
<name><surname>Kurtz</surname><given-names>A.</given-names></name>
<name><surname>Schweda</surname><given-names>F.</given-names></name>
<name><surname>Todorov</surname><given-names>V.</given-names></name>
<name><surname>Wagner</surname><given-names>C.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Physiology of kidney renin</article-title>. <source>Physiol Rev</source> <volume>90</volume>: <fpage>607</fpage>–<lpage>673</lpage>.</citation>
</ref>
<ref id="bibr15-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chinn</surname><given-names>R.</given-names></name>
<name><surname>Dusterdieck</surname><given-names>G.</given-names></name>
</person-group> (<year>1972</year>). <article-title>The response of blood pressure to infusion of angiotensin II: relation to plasma concentrations of renin and angiotensin II</article-title>. <source>Clin Sci</source> <volume>42</volume>: <fpage>489</fpage>–<lpage>504</lpage>.</citation>
</ref>
<ref id="bibr16-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dahlöf</surname><given-names>B.</given-names></name>
<name><surname>Anderson</surname><given-names>D.</given-names></name>
<name><surname>Arora</surname><given-names>V.</given-names></name>
<name><surname>Bush</surname><given-names>C.</given-names></name>
<name><surname>Keefe</surname><given-names>D.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension</article-title>. <source>J Clin Hypertens</source> <volume>9</volume> <supplement>Suppl A</supplement>(<issue>5</issue>): <fpage>A157 P</fpage>–<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr17-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Danser</surname><given-names>A.</given-names></name>
<name><surname>van Kats</surname><given-names>J.</given-names></name>
<name><surname>Admiraal</surname><given-names>P.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis</article-title>. <source>Hypertension</source> <volume>24</volume>: <fpage>37</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr18-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Danser</surname><given-names>A.</given-names></name>
<name><surname>van Kesteren</surname><given-names>C.</given-names></name>
<name><surname>Bax</surname><given-names>W.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Prorenin, renin, angiotensin, and angiotensin converting enzyme in normal and failing hearts: evidence for renin binding</article-title>. <source>Circulation</source> <volume>96</volume>: <fpage>220</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr19-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Gasparo</surname><given-names>M.</given-names></name>
<name><surname>Catt</surname><given-names>K.</given-names></name>
<name><surname>Inagami</surname><given-names>T.</given-names></name>
<name><surname>Wright</surname><given-names>J.</given-names></name>
<name><surname>Unger</surname><given-names>T</given-names></name>
</person-group>. (<year>2000</year>) <article-title>International Union of Pharmacology XXIII. The angiotensin II receptors</article-title>. <source>Pharmacol Rev</source> <volume>52</volume>: <fpage>415</fpage>–<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr20-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deinum</surname><given-names>J.</given-names></name>
<name><surname>Ronn</surname><given-names>B.</given-names></name>
<name><surname>Mathiesen</surname><given-names>E.</given-names></name>
<name><surname>Derkx</surname><given-names>F.</given-names></name>
<name><surname>Hop</surname><given-names>W.</given-names></name>
<name><surname>Schalekamp</surname><given-names>M.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus</article-title>. <source>Diabetologia</source> <volume>42</volume>: <fpage>1006</fpage>–<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr21-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dell’Italia</surname><given-names>L</given-names></name>
</person-group>. (<year>2011</year>) <article-title>Translational success stories: angiotensin receptor 1 antagonists in heart failure</article-title>. <source>Circ Res</source> <volume>109</volume>: <fpage>437</fpage>–<lpage>452</lpage>.</citation>
</ref>
<ref id="bibr22-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dostal</surname><given-names>D.</given-names></name>
</person-group> (<year>2000</year>) <article-title>The cardiac renin–angiotensin system: novel signaling mechanisms related to cardiac growth and function</article-title>. <source>Regul Pept</source> <volume>91</volume>: <fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr23-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drummond</surname><given-names>W.</given-names></name>
<name><surname>Munger</surname><given-names>M.</given-names></name>
<name><surname>Rafique Essop</surname><given-names>M.</given-names></name>
<name><surname>Maboudian</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>M.</given-names></name>
<name><surname>Keefe</surname><given-names>D.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy</article-title>. <source>J Clin Hypertens</source> <volume>9</volume>: <fpage>742</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr24-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duprez</surname><given-names>D.</given-names></name>
<name><surname>Munger</surname><given-names>M.</given-names></name>
<name><surname>Botha</surname><given-names>J.</given-names></name>
<name><surname>Keefe</surname><given-names>D.</given-names></name>
<name><surname>Charney</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial</article-title>. <source>J Hum Hypertens</source> <volume>24</volume>: <fpage>600</fpage>–<lpage>608</lpage>.</citation>
</ref>
<ref id="bibr25-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frampton</surname><given-names>J.</given-names></name>
<name><surname>Curran</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Aliskiren: a review of its use in the management of hypertension</article-title>. <source>Drugs</source> <volume>67</volume>: <fpage>1767</fpage>–<lpage>1792</lpage>.</citation>
</ref>
<ref id="bibr26-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freiberger</surname><given-names>V.</given-names></name>
<name><surname>Amann</surname><given-names>K.</given-names></name>
<name><surname>Heemann</surname><given-names>U.</given-names></name>
<name><surname>Frank</surname><given-names>H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Effect of a triple blockade of the renin–angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation</article-title>. <source>Transpl Int</source> <volume>22</volume>: <fpage>1110</fpage>–<lpage>1113</lpage>.</citation>
</ref>
<ref id="bibr27-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ganong</surname><given-names>W.</given-names></name>
<name><surname>Mulrow</surname><given-names>P.</given-names></name>
<name><surname>Boeryczka</surname><given-names>A.</given-names></name>
<name><surname>Cera</surname><given-names>G.</given-names></name>
</person-group> (<year>1962</year>) <article-title>Evidence for a direct effect of angiotensin II on adrenal cortex of the dog</article-title>. <source>Exp Biol Med</source> <volume>109</volume>: <fpage>381</fpage>–<lpage>384</lpage>.</citation>
</ref>
<ref id="bibr28-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gifford</surname><given-names>R.</given-names><suffix>Jr.</suffix></name>
</person-group> (<year>1974</year>) <article-title>Drug combinations as rational antihypertensive therapy</article-title>. <source>MD Arch Intern Med</source> <volume>133</volume>: <fpage>1053</fpage>–<lpage>1057</lpage>.</citation>
</ref>
<ref id="bibr29-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorbea-Oppliger</surname><given-names>V.</given-names></name>
<name><surname>Melaragno</surname><given-names>M.</given-names></name>
<name><surname>Potter</surname><given-names>G.</given-names></name>
<name><surname>Petit</surname><given-names>R.</given-names></name>
<name><surname>Fink</surname><given-names>G.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects</article-title>. <source>J Pharmacol Exp Ther</source> <volume>271</volume>: <fpage>804</fpage>–<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr30-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gradman</surname><given-names>A.</given-names></name>
<name><surname>Flack</surname><given-names>J.</given-names></name>
<name><surname>Arora</surname><given-names>V.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: a pooled analysis of 1612 patients with hypertension</article-title>. <source>Circulation</source> <volume>114</volume>(<supplement>18 Suppl.</supplement>): <fpage>II</fpage>-<lpage>773</lpage>. Abstract 3620.</citation>
</ref>
<ref id="bibr31-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gradman</surname><given-names>A.</given-names></name>
<name><surname>Schmieder</surname><given-names>R.</given-names></name>
<name><surname>Lins</surname><given-names>R.</given-names></name>
<name><surname>Nussberger</surname><given-names>J.</given-names></name>
<name><surname>Chiang</surname><given-names>Y.</given-names></name>
<name><surname>Bedigian</surname><given-names>M.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients</article-title>. <source>Circulation</source> <volume>111</volume>: <fpage>1012</fpage>–<lpage>1018</lpage>.</citation>
</ref>
<ref id="bibr32-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harel</surname><given-names>Z.</given-names></name>
<name><surname>Gilbert</surname><given-names>C.</given-names></name>
<name><surname>Wald</surname><given-names>R.</given-names></name>
<name><surname>Bell</surname><given-names>C.</given-names></name>
<name><surname>Perl</surname><given-names>J.</given-names></name>
<name><surname>Juurlink</surname><given-names>D.</given-names></name>
</person-group> (<year>2012</year>) <article-title>The effect of combination treatment with aliskiren and blockers of the renin–angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis</article-title>. <source>BMJ</source> <volume>344</volume>: <fpage>e42</fpage>.</citation>
</ref>
<ref id="bibr33-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hilgers</surname><given-names>K.</given-names></name>
<name><surname>Veelken</surname><given-names>R.</given-names></name>
<name><surname>Müller</surname><given-names>D.</given-names></name>
<name><surname>Kohler</surname><given-names>H.</given-names></name>
<name><surname>Hartner</surname><given-names>A.</given-names></name>
<name><surname>Botkin</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Renin uptake by the endothelium mediates vascular angiotensin formation</article-title>. <source>Hypertension</source> <volume>38</volume>: <fpage>243</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr34-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hollenberg</surname><given-names>N.</given-names></name>
<name><surname>Fisher</surname><given-names>N.</given-names></name>
<name><surname>Price</surname><given-names>D.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system</article-title>. <source>Hypertension</source> <volume>32</volume>: <fpage>387</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr35-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holtkamp</surname><given-names>F.</given-names></name>
<name><surname>de Zeeuw</surname><given-names>D.</given-names></name>
<name><surname>Thomas</surname><given-names>M.</given-names></name>
<name><surname>Cooper</surname><given-names>M.</given-names></name>
<name><surname>de Graeff</surname><given-names>P.</given-names></name>
<name><surname>Hillege</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a lower decrease in long-term renal function</article-title>. <source>Kidney Int</source> <volume>80</volume>: <fpage>282</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr36-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jafar</surname><given-names>T.</given-names></name>
<name><surname>Schmid</surname><given-names>C.</given-names></name>
<name><surname>Landa</surname><given-names>M.</given-names></name>
<name><surname>Giatras</surname><given-names>I.</given-names></name>
<name><surname>Toto</surname><given-names>R.</given-names></name>
<name><surname>Remuzzi</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data</article-title>. <source>Ann Intern Med</source>. <volume>135</volume>: <fpage>73</fpage>.</citation>
</ref>
<ref id="bibr37-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jennings</surname><given-names>D.</given-names></name>
<name><surname>Kalus</surname><given-names>J.</given-names></name>
<name><surname>Coleman</surname><given-names>C.</given-names></name>
<name><surname>Manierski</surname><given-names>C.</given-names></name>
<name><surname>Yee</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis</article-title>. <source>Diabet Med</source> <volume>24</volume>: <fpage>486</fpage>–<lpage>493</lpage>.</citation>
</ref>
<ref id="bibr38-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jordan</surname><given-names>J.</given-names></name>
<name><surname>Engeli</surname><given-names>S.</given-names></name>
<name><surname>Boye</surname><given-names>S.</given-names></name>
<name><surname>Le Breton</surname><given-names>S.</given-names></name>
<name><surname>Keefe</surname><given-names>D.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Renin inhibition in obesity hypertension</article-title>. <source>Hypertension</source> <volume>49</volume>: <fpage>1047</fpage>–<lpage>1055</lpage>.</citation>
</ref>
<ref id="bibr39-1753944713479995">
<citation citation-type="other">
<person-group person-group-type="author">
<name><surname>Kastrop</surname></name><etal/>
</person-group>. (<year>2010</year>)</citation>
</ref>
<ref id="bibr40-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kawazu</surname><given-names>S.</given-names></name>
<name><surname>Minagawa</surname><given-names>S.</given-names></name>
<name><surname>Yazawa</surname><given-names>M.</given-names></name>
<name><surname>Tsuchida</surname><given-names>A.</given-names></name>
<name><surname>Ihara</surname><given-names>C.</given-names></name>
<name><surname>Hosaka</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Sex difference and possible relationship to microvascular complications of serum prorenin levels in type 2 diabetic patients, measured by a novel antibody-activating direct enzyme kinetic assay</article-title>. <source>J Diabetes Complications</source> <volume>18</volume>: <fpage>275</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr41-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kifor</surname><given-names>I.</given-names></name>
<name><surname>Dzau</surname><given-names>V.</given-names></name>
</person-group> (<year>1987</year>) <article-title>Endothelial renin–angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins</article-title>. <source>Circ Res</source> <volume>60</volume>: <fpage>422</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr42-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kjeldsen</surname><given-names>S.</given-names></name>
<name><surname>Dahlöf</surname><given-names>B.</given-names></name>
<name><surname>Devereux</surname><given-names>R.</given-names></name>
<name><surname>Julius</surname><given-names>S.</given-names></name>
<name><surname>Aurup</surname><given-names>P.</given-names></name>
<name><surname>Edelman</surname><given-names>J.</given-names></name><etal/>
</person-group>. for <collab>the LIFE Study Group</collab> (<year>2002</year>) <article-title>Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a losartan intervention for endpoint reduction (LIFE) substudy</article-title>. <source>JAMA</source> <volume>288</volume>: <fpage>1491</fpage>–<lpage>1498</lpage>.</citation>
</ref>
<ref id="bibr43-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kostenis</surname><given-names>E.</given-names></name>
<name><surname>Milligan</surname><given-names>G.</given-names></name>
<name><surname>Christopoulos</surname><given-names>A.</given-names></name>
<name><surname>Sanchez-Ferrer</surname><given-names>C.</given-names></name>
<name><surname>Heringer-Walther</surname><given-names>S.</given-names></name>
<name><surname>Sexton</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Protein G–coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor</article-title>. <source>Circulation</source> <volume>111</volume>: <fpage>1806</fpage>–<lpage>1813</lpage>.</citation>
</ref>
<ref id="bibr44-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kramkowski</surname><given-names>K.</given-names></name>
<name><surname>Mogielnicki</surname><given-names>A.</given-names></name>
<name><surname>Buczko</surname><given-names>W.</given-names></name>
</person-group> (<year>2006</year>) <article-title>The physiological significance of the alternative pathways of angiotensin II production</article-title>. <source>J Physiol Pharmacol</source> <volume>57</volume>: <fpage>529</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr45-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krone</surname><given-names>W.</given-names></name>
<name><surname>Hanefeld</surname><given-names>M.</given-names></name>
<name><surname>Meyer</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome</article-title>. <source>J Human Hypertension</source> <volume>25</volume>: <fpage>186</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr46-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krop</surname><given-names>M.</given-names></name>
<name><surname>Garrelds</surname><given-names>I.</given-names></name>
<name><surname>de Bruin</surname><given-names>R.</given-names></name>
<name><surname>van Gool</surname><given-names>J.</given-names></name>
<name><surname>Fisher</surname><given-names>N.</given-names></name>
<name><surname>Hollenberg</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Aliskiren accumulates in renin secretory granules and binds plasma prorenin</article-title>. <source>Hypertension</source> <volume>52</volume>: <fpage>1076</fpage>–<lpage>1083</lpage>.</citation>
</ref>
<ref id="bibr47-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Boim</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Diversity of pathways for intracellular angiotensin II synthesis</article-title>. <source>Curr Opin Nephrol Hypertension</source> <volume>18</volume>: <fpage>33</fpage>-<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr48-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kunz</surname><given-names>R.</given-names></name>
<name><surname>Friedrich</surname><given-names>C.</given-names></name>
<name><surname>Wolbers</surname><given-names>M.</given-names></name>
<name><surname>Mann</surname><given-names>J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria and renal disease</article-title>. <source>Ann Intern Med</source> <volume>148</volume>: <fpage>30</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr49-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laragh</surname><given-names>J.</given-names></name>
</person-group> (<year>1973</year>) <article-title>Vasoconstriction-volume analysis for understanding and treating hypertension: The use of renin and aldosterone profiles</article-title>. <source>Am J Med</source> <volume>55</volume>: <fpage>261</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr50-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Latini</surname><given-names>R.</given-names></name>
<name><surname>Masson</surname><given-names>S.</given-names></name>
<name><surname>Anand</surname><given-names>I.</given-names></name>
<name><surname>Judd</surname><given-names>D.</given-names></name>
<name><surname>Maggioni</surname><given-names>A.</given-names></name>
<name><surname>Chiang</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT)</article-title> <source>Circulation</source> <volume>106</volume>: <fpage>2454</fpage>–<lpage>2458</lpage>.</citation>
</ref>
<ref id="bibr51-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee-Kirsch</surname><given-names>M.</given-names></name>
<name><surname>Gaudet</surname><given-names>F.</given-names></name>
<name><surname>Cardoce</surname><given-names>M.</given-names></name>
<name><surname>Lindpainter</surname><given-names>K.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Distinct renin isoform generated by tissue-specific transcription initiation and alternative splicing</article-title>. <source>Circ Res</source> <volume>84</volume>: <fpage>240</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr52-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Linz</surname><given-names>W.</given-names></name>
<name><surname>Wiemer</surname><given-names>G.</given-names></name>
<name><surname>Gohlke</surname><given-names>P.</given-names></name>
<name><surname>Unger</surname><given-names>T.</given-names></name>
<name><surname>Schölkens</surname><given-names>B.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Contribution of kinins to the cardiovascular actions of angiotensin converting enzyme inhibitors</article-title>. <source>Pharmacol Rev</source> <volume>47</volume>: <fpage>25</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr53-1753944713479995">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Man in′t Veld</surname><given-names>A.</given-names></name>
<name><surname>den Meiracker</surname><given-names>A</given-names></name>
</person-group>. (<year>1990</year>) <article-title>Effects of hypertensive drugs on cardiovascular hemodynamics</article-title>. In <person-group person-group-type="editor">
<name><surname>Laragh</surname><given-names>J.</given-names></name>
<name><surname>Brenner</surname><given-names>B.</given-names></name>
</person-group> (eds), <source>Hypertension. Pathophysiology, Diagnosis and Management</source>, <volume>vol. II</volume>. <publisher-loc>New York</publisher-loc>: <publisher-name>Raven Press</publisher-name>, pp. <fpage>2117</fpage>–<lpage>2130</lpage>.</citation>
</ref>
<ref id="bibr54-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mann</surname><given-names>J.</given-names></name>
<name><surname>Schmieder</surname><given-names>R.</given-names></name>
<name><surname>McQueen</surname><given-names>M.</given-names></name>
<name><surname>Dyal</surname><given-names>L.</given-names></name>
<name><surname>Schumacher</surname><given-names>H.</given-names></name>
<name><surname>Pogue</surname><given-names>J.</given-names></name><etal/>
</person-group>. <collab>for the ONTARGET Investigators</collab> (<year>2008</year>) <article-title>Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial</article-title>. <source>Lancet</source> <volume>372</volume>: <fpage>547</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr55-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mason</surname><given-names>P.</given-names></name>
<name><surname>Fraser</surname><given-names>J.</given-names></name>
<name><surname>Morton</surname><given-names>J.</given-names></name>
<name><surname>Semple</surname><given-names>P.</given-names></name>
<name><surname>Wilson</surname><given-names>A.</given-names></name>
</person-group> (<year>1976</year>) <article-title>The effect of angiotensin II infusion on plasma corticosteroid concentrations in normal man</article-title>. <source>J Steroid Biochem</source> <volume>7</volume>: <fpage>859</fpage>-<lpage>861</lpage>.</citation>
</ref>
<ref id="bibr56-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMurray</surname><given-names>J.</given-names></name>
<name><surname>Pitt</surname><given-names>B.</given-names></name>
<name><surname>Latini</surname><given-names>R.</given-names></name>
<name><surname>Maggioni</surname><given-names>A.</given-names></name>
<name><surname>Solomon</surname><given-names>S.</given-names></name>
<name><surname>Keefe</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure</article-title>. <source>Circ Heart Failure</source> <volume>1</volume>: <fpage>17</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr57-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Menard</surname><given-names>J.</given-names></name>
<name><surname>Azizi</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>)<article-title>The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren</article-title>. <source>J Hypertens</source> <volume>25</volume>: <fpage>1775</fpage>–<lpage>1782</lpage>.</citation>
</ref>
<ref id="bibr58-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mogensen</surname><given-names>C.</given-names></name>
<name><surname>Neldam</surname><given-names>S.</given-names></name>
<name><surname>Tikkanen</surname><given-names>I.</given-names></name>
<name><surname>Oren</surname><given-names>S.</given-names></name>
<name><surname>Viskoper</surname><given-names>R.</given-names></name>
<name><surname>Watts</surname><given-names>R.</given-names></name>
<name><surname>Cooper</surname><given-names>M.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study</article-title>. <source>Br Med J</source> <volume>321</volume>: <fpage>1440</fpage>–<lpage>1444</lpage>.</citation>
</ref>
<ref id="bibr59-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mendez</surname><given-names>M.</given-names></name>
<name><surname>Gross</surname><given-names>K.</given-names></name>
<name><surname>Glenn</surname><given-names>S.</given-names></name>
<name><surname>Garvin</surname><given-names>J.</given-names></name>
<name><surname>Carretero</surname><given-names>O.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Vesicle-associated membrane protein-2 (VAMP2) mediates cAMP-stimulated renin release in mouse juxtaglomerular cells</article-title>. <source>J Biol Chem</source> <volume>286</volume>: <fpage>28608</fpage>–<lpage>28618</lpage>.</citation>
</ref>
<ref id="bibr60-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mogi</surname><given-names>M.</given-names></name>
<name><surname>Iwai</surname><given-names>M.</given-names></name>
<name><surname>Horiuchi</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>27</volume>: <fpage>2532</fpage>–<lpage>2539</lpage>.</citation>
</ref>
<ref id="bibr61-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muhlestein</surname><given-names>J.</given-names></name>
<name><surname>May</surname><given-names>H.</given-names></name>
<name><surname>Bair</surname><given-names>T.</given-names></name>
<name><surname>Prescott</surname><given-names>M.</given-names></name>
<name><surname>Horne</surname><given-names>B.</given-names></name>
<name><surname>White</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease</article-title>. <source>Am J Cardiol</source> <volume>106</volume>: <fpage>764</fpage>–<lpage>769</lpage>.</citation>
</ref>
<ref id="bibr62-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakao</surname><given-names>N.</given-names></name>
<name><surname>Seno</surname><given-names>H.</given-names></name>
<name><surname>Kasuga</surname><given-names>H.</given-names></name>
<name><surname>Toriyama</surname><given-names>T.</given-names></name>
<name><surname>Kawahara</surname><given-names>H.</given-names></name>
<name><surname>Fukagawa</surname><given-names>M</given-names></name>
</person-group>. (<year>2004</year>) <article-title>Combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP Substudy</article-title>, <source>Am J Nephrol</source> <volume>24</volume>: <fpage>543</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr63-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Navar</surname><given-names>L.</given-names></name>
<name><surname>Nishiyama</surname><given-names>A.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Intrarenal formation of angiotensin II</article-title>. <source>Contrib Nephrol</source> <volume>10</volume>: <fpage>1</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr64-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Navar</surname><given-names>L.</given-names></name>
<name><surname>Nishiyama</surname><given-names>A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Why are angiotensin concentrations so high in the kidney?</article-title> <source>Curr Opin Nephrol Hypertens</source> <volume>13</volume>: <fpage>107</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr65-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neves</surname><given-names>F.</given-names></name>
<name><surname>Duncan</surname><given-names>K.</given-names></name>
<name><surname>Baxter</surname><given-names>J.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Cathepsin B is a prorenin processing enzyme</article-title>. <source>Hypertension</source> <volume>27</volume>: <fpage>514</fpage>–<lpage>517</lpage>.</citation>
</ref>
<ref id="bibr66-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>G.</given-names></name>
<name><surname>Danser</surname><given-names>A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents</article-title>. <source>Experiment Physiol</source> <volume>93</volume>: <fpage>557</fpage>–<lpage>563</lpage>.</citation>
</ref>
<ref id="bibr67-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nussberger</surname><given-names>J.</given-names></name>
<name><surname>Wuerzner</surname><given-names>G.</given-names></name>
<name><surname>Jensen</surname><given-names>C.</given-names></name>
<name><surname>Brunner</surname><given-names>H.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalapril</article-title>. <source>Hypertension</source> <volume>39</volume>: <fpage>E1</fpage>–<lpage>E8</lpage>.</citation>
</ref>
<ref id="bibr68-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>E.</given-names></name>
<name><surname>Barton</surname><given-names>J.</given-names></name>
<name><surname>Nussberger</surname><given-names>J.</given-names></name>
<name><surname>Mulcahy</surname><given-names>D.</given-names></name>
<name><surname>Jensen</surname><given-names>C.</given-names></name>
<name><surname>Dicker</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker</article-title>. <source>Hypertension</source> <volume>49</volume>: <fpage>276</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr69-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oparil</surname><given-names>S.</given-names></name>
<name><surname>Yarows</surname><given-names>S.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Satlin</surname><given-names>A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>The direct renin inhibitor aliskiren in combination with valsartan provides additional blood pressure-lowering effects compared with either agent alone in patients with hypertension</article-title>. <source>J Clin Hypertens</source> <volume>9</volume> <supplement>Suppl A</supplement>(<issue>5</issue>): <fpage>A174 P</fpage>–<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr70-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parving</surname><given-names>H.</given-names></name>
<name><surname>Persson</surname><given-names>F.</given-names></name>
<name><surname>Lewis</surname><given-names>J.</given-names></name>
<name><surname>Lewis</surname><given-names>E.</given-names></name>
<name><surname>Hollenberg</surname><given-names>N</given-names></name>
</person-group>. <collab>for the AVOID Study Investigators</collab> (<year>2008</year>) <article-title>Aliskiren combined with losartan in type 2 diabetes and nephropathy</article-title>. <source>N Engl J Med</source> <volume>358</volume>: <fpage>2433</fpage>–<lpage>2446</lpage>.</citation>
</ref>
<ref id="bibr71-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parving</surname><given-names>H.</given-names></name>
<name><surname>Brenner</surname><given-names>B.</given-names></name>
<name><surname>McMurray</surname><given-names>J.</given-names></name>
<name><surname>de Zeeuw</surname><given-names>D.</given-names></name>
<name><surname>Haffner</surname><given-names>S.</given-names></name>
<name><surname>Solomon</surname><given-names>S.</given-names></name><etal/>
</person-group>. <collab>for the ALTITUDE Investigators</collab> (<year>2012</year>) <article-title>Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes</article-title>. <source>N Engl J Med</source> <volume>367</volume>: <fpage>2204</fpage>–<lpage>2213</lpage>.</citation>
</ref>
<ref id="bibr72-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paul</surname><given-names>M.</given-names></name>
<name><surname>Mahr</surname><given-names>A.</given-names></name>
<name><surname>Kreutz</surname><given-names>R.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Physiology of local renin–angiotensin systems</article-title>. <source>Physiol Rev</source> <volume>86</volume>: <fpage>747</fpage>–<lpage>803</lpage>.</citation>
</ref>
<ref id="bibr73-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pendergrass</surname><given-names>K.</given-names></name>
<name><surname>Averill</surname><given-names>D.</given-names></name>
<name><surname>Ferrario</surname><given-names>C.</given-names></name>
<name><surname>Diz</surname><given-names>D.</given-names></name>
<name><surname>Chappell</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2. Lewis rat</article-title>. <source>Am J Physiol</source> <volume>290</volume>: <fpage>F1497</fpage>–<lpage>F1506</lpage>.</citation>
</ref>
<ref id="bibr74-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pfeffer</surname><given-names>M.</given-names></name>
<name><surname>McMurray</surname><given-names>J.</given-names></name>
<name><surname>Velazquez</surname><given-names>E.</given-names></name>
<name><surname>Rouleau</surname><given-names>J.</given-names></name>
<name><surname>Kober</surname><given-names>L.</given-names></name>
<name><surname>Maggioni</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both</article-title>. <source>N Engl J Med</source> <volume>349</volume>: <fpage>1893</fpage>–<lpage>1906</lpage>.</citation>
</ref>
<ref id="bibr75-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitt</surname><given-names>B.</given-names></name>
<name><surname>Poole-Wilson</surname><given-names>P.</given-names></name>
<name><surname>Segal</surname><given-names>R.</given-names></name>
<name><surname>Martinez</surname><given-names>F.</given-names></name>
<name><surname>Dickstein</surname><given-names>K.</given-names></name>
<name><surname>Camm</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial — the Losartan Heart Failure Survival Study ELITE II</article-title>. <source>Lancet</source> <volume>355</volume>: <fpage>1582</fpage>–<lpage>1587</lpage>.</citation>
</ref>
<ref id="bibr76-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Re</surname><given-names>R.</given-names></name>
</person-group> (<year>2001</year>) <article-title>The clinical implication of tissue renin angiotensin systems</article-title>. <source>Curr Opin Cardiol</source> <volume>16</volume>: <fpage>317</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr77-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Re</surname><given-names>R.</given-names></name>
</person-group> (<year>2003a</year>) <article-title>Implications of intracrine hormone action for physiology and medicine</article-title>. <source>J Physiol - Heart Circ Physiol</source> <volume>284</volume>: <fpage>H751</fpage>–<lpage>H757</lpage>.</citation>
</ref>
<ref id="bibr78-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Re</surname><given-names>R.</given-names></name>
</person-group> (<year>2003b</year>) <article-title>Intracellular renin and the nature of intracrine enzymes</article-title>. <source>Hypertension</source> <volume>42</volume>: <fpage>117</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr79-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reudelhuber</surname><given-names>T.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Truncated prorenin comes up… short</article-title>. <source>Hypertension</source> <volume>54</volume>: <fpage>1216</fpage>–<lpage>1217</lpage>.</citation>
</ref>
<ref id="bibr80-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saris</surname><given-names>J.</given-names></name>
<name><surname>’t Hoen</surname><given-names>P.</given-names></name>
<name><surname>Garrelds</surname><given-names>I.</given-names></name>
<name><surname>Dekkers</surname><given-names>D.</given-names></name>
<name><surname>den Dunnen</surname><given-names>J.</given-names></name>
<name><surname>Lamers</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II</article-title>. <source>Hypertension</source> <volume>48</volume>: <fpage>564</fpage>–<lpage>571</lpage>.</citation>
</ref>
<ref id="bibr81-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schalenkamp</surname><given-names>M.</given-names></name>
<name><surname>Danser</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Facilitated diffusion of angiotensin II from perivascular interstitium to AT1 receptor of the arteriole. A regulating step in vasoconstriction</article-title>. <source>J Hypertens</source> <volume>29</volume>: <fpage>906</fpage>–<lpage>914</lpage>.</citation>
</ref>
<ref id="bibr82-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmieder</surname><given-names>R.</given-names></name>
<name><surname>Philipp</surname><given-names>T.</given-names></name>
<name><surname>Guerediaga</surname><given-names>J.</given-names></name>
<name><surname>Gorostidi</surname><given-names>M.</given-names></name>
<name><surname>Smith</surname><given-names>B.</given-names></name>
<name><surname>Weissbach</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide</article-title>. <source>Circulation</source> <volume>119</volume>: <fpage>417</fpage>–<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr83-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schrader</surname><given-names>J.</given-names></name>
<name><surname>Lüders</surname><given-names>S.</given-names></name>
<name><surname>Kulschewski</surname><given-names>A.</given-names></name>
<name><surname>Hammersen</surname><given-names>F.</given-names></name>
<name><surname>Plate</surname><given-names>K.</given-names></name>
<name><surname>Berger</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)</article-title>. <source>Stroke</source> <volume>36</volume>: <fpage>1218</fpage>–<lpage>1224</lpage>.</citation>
</ref>
<ref id="bibr84-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sealey</surname><given-names>J.</given-names></name>
<name><surname>Laragh</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion</article-title> <month>may</month> <article-title>limit its effectiveness</article-title>. <source>Am J Hypertens</source> <volume>20</volume>: <fpage>587</fpage>–<lpage>597</lpage>.</citation>
</ref>
<ref id="bibr85-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sealey</surname><given-names>J.</given-names></name>
<name><surname>Laragh</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises</article-title>. <source>Am J Hypertens</source> <volume>22</volume>: <fpage>112</fpage>–<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr86-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sica</surname><given-names>D.</given-names></name>
<name><surname>Andersen</surname><given-names>K.</given-names></name>
<name><surname>Oh</surname><given-names>B.</given-names></name><etal/>
</person-group>(<year>2008</year>) <article-title>Effects of aliskiren on blood pressure and plasma renin activity persist after stopping treatment in patients with hypertension</article-title>. <source>J Clin Hypertens</source> <volume>10</volume>: <fpage>A34</fpage>–<lpage>A35</lpage>.</citation>
</ref>
<ref id="bibr87-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>V.</given-names></name>
<name><surname>Baker</surname><given-names>K.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Activation of the intracellular renin–angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production</article-title>. <source>Am J Physiol - Heart Circ Physiol</source> <volume>294</volume>: <fpage>H1675</fpage>–<lpage>H1684</lpage>.</citation>
</ref>
<ref id="bibr88-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solomon</surname><given-names>S.</given-names></name>
<name><surname>Appelbaum</surname><given-names>E.</given-names></name>
<name><surname>Manning</surname><given-names>W.</given-names></name>
<name><surname>Verma</surname><given-names>A.</given-names></name>
<name><surname>Berglund</surname><given-names>T.</given-names></name>
<name><surname>Lukashevich</surname><given-names>V.</given-names></name><etal/>
</person-group>. for <collab>the Aliskiren in Left Ventricular Hypertrophy (ALLAY)</collab> (<year>2009</year>) <article-title>Trial Investigators Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy</article-title>. <source>Circulation</source> <volume>119</volume>: <fpage>530</fpage>–<lpage>537</lpage>.</citation>
</ref>
<ref id="bibr89-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stanton</surname><given-names>A.</given-names></name>
<name><surname>Dicker</surname><given-names>P.</given-names></name>
<name><surname>O’Brien</surname><given-names>E</given-names></name>
</person-group>. (<year>2009</year>) <article-title>Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively</article-title>. <source>Am J Hypertens</source> <volume>22</volume>: <fpage>954</fpage>–<lpage>957</lpage>.</citation>
</ref>
<ref id="bibr90-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stanton</surname><given-names>A.</given-names></name>
<name><surname>Gradman</surname><given-names>A.</given-names></name>
<name><surname>Schmieder</surname><given-names>R.</given-names></name>
<name><surname>Nussberger</surname><given-names>J.</given-names></name>
<name><surname>Sarangapani</surname><given-names>R.</given-names></name>
<name><surname>Prescott</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Aliskiren monotherapy does not cause paradoxical blood pressure rises. Meta-analysis of data from 8 clinical trials</article-title>. <source>Hypertension</source> <volume>55</volume>: <fpage>54</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr91-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stanton</surname><given-names>A.</given-names></name>
<name><surname>Jensen</surname><given-names>C.</given-names></name>
<name><surname>Nussberger</surname><given-names>J.</given-names></name>
<name><surname>O’Brien</surname><given-names>E</given-names></name>
</person-group>. (<year>2003</year>) <article-title>Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren</article-title>. <source>Hypertension</source> <volume>42</volume>: <fpage>1137</fpage>–<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr92-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uresin</surname><given-names>Y.</given-names></name>
<name><surname>Taylor</surname><given-names>A.</given-names></name>
<name><surname>Kilo</surname><given-names>C.</given-names></name>
<name><surname>Tschöpe</surname><given-names>D.</given-names></name>
<name><surname>Santonastaso</surname><given-names>M.</given-names></name>
<name><surname>Ibram</surname><given-names>G.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Satlin</surname><given-names>A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension</article-title>. <source>J Renin Angiotensin Aldosterone System</source> <volume>8</volume>: <fpage>190</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr93-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van de Wal</surname><given-names>R.</given-names></name>
<name><surname>van der Harst</surname><given-names>P.</given-names></name>
<name><surname>Wagenaar</surname><given-names>L.</given-names></name>
<name><surname>Wassmann</surname><given-names>S.</given-names></name>
<name><surname>Morshuis</surname><given-names>W.</given-names></name>
<name><surname>Nickenig</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease</article-title>. <source>J Cardiovasc Pharmacol</source> <volume>50</volume>: <fpage>372</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr94-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verdecchia</surname><given-names>P.</given-names></name>
<name><surname>Angeli</surname><given-names>F.</given-names></name>
<name><surname>Mazzotta</surname><given-names>G.</given-names></name>
<name><surname>Martire</surname><given-names>P.</given-names></name>
<name><surname>Garofoli</surname><given-names>M.</given-names></name>
<name><surname>Gentile</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Aliskiren versus ramipril in hypertension</article-title>. <source>Ther Adv Cardiovasc Dis</source> <volume>4</volume>: <fpage>193</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr95-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villamil</surname><given-names>A.</given-names></name>
<name><surname>Chrysant</surname><given-names>S.</given-names></name>
<name><surname>Calhoun</surname><given-names>D.</given-names></name>
<name><surname>Schober</surname><given-names>B.</given-names></name>
<name><surname>Hsu</surname><given-names>H.</given-names></name>
<name><surname>Matrisciano-Dimichino</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide</article-title>. <source>J Hypertension</source> <volume>25</volume>: <fpage>217</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr96-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weir</surname><given-names>M.</given-names></name>
<name><surname>Bush</surname><given-names>C.</given-names></name>
<name><surname>Anderson</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Keefe</surname><given-names>D.</given-names></name>
<name><surname>Satin</surname><given-names>A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor Aliskiren in patients with hypertension: a pooled analysis</article-title>. <source>J Am Soc Hypertens</source> <volume>1</volume>(<issue>4</issue>): <fpage>264</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr97-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wing</surname><given-names>L.</given-names></name>
<name><surname>Reid</surname><given-names>C.</given-names></name>
<name><surname>Ryan</surname><given-names>P.</given-names></name>
<name><surname>Beilin</surname><given-names>L.</given-names></name>
<name><surname>Brown</surname><given-names>M.</given-names></name>
<name><surname>Jennings</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia</article-title>. <source>Clin Exp Hypertens</source> <volume>9</volume>: <fpage>779</fpage>–<lpage>791</lpage>.</citation>
</ref>
<ref id="bibr98-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolf</surname><given-names>G.</given-names></name>
<name><surname>Ritz</surname><given-names>E.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications</article-title>. <source>Kidney Int</source> <volume>67</volume>: <fpage>799</fpage>–<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr99-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolny</surname><given-names>A.</given-names></name>
<name><surname>Clozel</surname><given-names>J.</given-names></name>
<name><surname>Rein</surname><given-names>J.</given-names></name>
<name><surname>Mory</surname><given-names>P.</given-names></name>
<name><surname>Vogt</surname><given-names>P.</given-names></name>
<name><surname>Turino</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Functional and biochemical analysis of angiotensin II-forming pathways in the human heart</article-title>. <source>Circulation Res</source> <volume>80</volume>: <fpage>219</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr100-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yarows</surname><given-names>S.</given-names></name>
<name><surname>Oparil</surname><given-names>S.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Arora</surname><given-names>V.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group> (<year>2008</year>). <article-title>Aliskiren in combination with valsartan provides additional blood pressure-lowering effects compared with either agent alone in elderly and younger patients with hypertension</article-title>. <source>J Hypertens</source> <volume>26</volume>(<issue>Suppl 1</issue>): <fpage>S19</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr101-1753944713479995">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yusuf</surname><given-names>S.</given-names></name>
<name><surname>Teo</surname><given-names>K.</given-names></name>
<name><surname>Pogue</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Telmisartan, ramipril, or both in patients at high risk for vascular events</article-title>. <source>N Engl J Med</source> <volume>358</volume>: <fpage>1547</fpage>–<lpage>1559</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>